Therefore, several guidelines endorse routine genetic testing of the five leading oncogenes EGFR, ALK, ROS1, BRAF and NTRK in newly metastatic non-squamous NSCLC patients, while other molecular targets, such as HER2 and KRAS mutations are approaching clinical practice [20,21,22]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.